首页> 美国卫生研究院文献>Cancer Cell International >Ibrutinib in B-cell lymphoma: single fighter might be enough?
【2h】

Ibrutinib in B-cell lymphoma: single fighter might be enough?

机译:伊布洛替尼在B细胞淋巴瘤中:单人战斗机可能足够?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Structure of Bruton’s tyrosine kinase (BTK) and associated cross-linking signaling pathways. a BTK comprises five structural domains. BTK activation occurs twice during phosphorylation upon the plasma membrane. The first phosphorylation occurs on the Tyr551 site within the kinase domain by the Syk or Src family kinase, which subsequently leads to autophosphorylation of Tyr223 in the SH3 domain, achieving full activation of BTK kinase activity. b BTK activation process and inhibited result of cross-linking pathways by BTK inhibitors. The left figure shows when extracellular antigen bond BCR, BTK can regulate adverse cellular biological processes by activating multiple important pathways, such as NF-kB, MAPK, NFAT, and mTOR pathway. The right figure shows when the BCR pathway is irreversibly inhibited by small-molecule BTK inhibitors, its downstream pathway such as NF-kB, MAPK, and NFAT will also be inhibited, resulting in anti-tumor activity in B cell lymphoma
机译:布鲁顿酪氨酸激酶(BTK)的结构和相关交联信号通路。 BTK包括五个结构域。在质膜上磷酸化期间,BTK活化发生两次。第一种磷酸化发生在激酶结构域内的Tyr551位点,Syk或SRC家族激酶随后导致SH3结构域中的Tyr223的自磷酸化,实现了BTK激酶活性的全激活。 B BTK活化过程和BTK抑制剂交联途径的抑制结果。左图显示当细胞外抗原BCR时,BTK可以通过激活多个重要途径来调节不良细胞生物过程,例如NF-KB,MAPK,NFAT和MTOR途径。右图表明,当BCR路径被小分子BTK抑制剂不可逆转地抑制,其下游途径如NF-KB,MAPK和NFAT也将被抑制,导致B细胞淋巴瘤中的抗肿瘤活性

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号